Clinical trials: SARS-CoV-2
SARS-CoV-2 Infection
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile.
- Trial name
- NCT04636697
- Testing
- Intramuscular injection, Intramuscular vaccine
- Where
- 91 sites in United States, Argentina and 4 more
- Volunteers
- 30,918 people, healthy volunteers welcome
- Sponsor
- Medicago
COVID-19
Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak
The recent COVID-19 outbreak is very challenging as data are distributed instantly on the data are very rapidly distributed through professional and non professional sources which may impact the management of the disease
- Trial name
- NCT04319315
- Testing
- survey
- Where
- Egypt
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Assiut University
COVID-19, SARS-CoV2 Infection
COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests
The aim of the COVAG study (Covid-19 Antigen study) is to assess the diagnostic efficacy of two of the most used rapid antigen tests (Roche \& Abbott).
- Conditions
- COVID-19, SARS-CoV2 Infection, SARS (Disease)
- Trial name
- COVAG (NCT05074017)
- Testing
- 3 nasopharyngeal swab
- Where
- 2 sites in Germany
- Volunteers
- 2,222 people, healthy volunteers welcome
- Sponsor
- Synlab Holding Deutschland GmbH
Long COVID
Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19
The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the…
- Trial name
- NCT06311435
- Testing
- RNA Biomarker Blood Test
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- MaxWell Clinic, PLC
Heart Failure
Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors >50 years old.
- Trial name
- NCT04983823
- Testing
- Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP), Usual care
- Where
- Australia
- Volunteers
- 820 people, healthy volunteers welcome
- Sponsor
- Baker Heart and Diabetes Institute
Covid19
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the…
- Trial name
- NCT04839042
- Testing
- SC-Ad6-1
- Where
- Australia
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Moat Biotechnology Corporation
Anti-SARS-CoV-2 Antibody Response
Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines
The investigators aim to evaluate the ability of a COVID-19 (Coronavirus disease) booster vaccine to induce a salivary antibody response and investigate a possible correlation with the serum antibody response and the cellular…
- Trial name
- CoVVacBoost (NCT05142540)
- Testing
- blood and saliva samples will be taken
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Hand Washing, Handwashing
The Effect of Behaviour Change Interventions on Use of Public Handwashing Stations in Bangladesh
As part of the COVID-19 response, BRAC has built 1000 public handwashing stations in several hundred villages in 20 sub-districts of Bangladesh.
- Conditions
- Hand Washing, Handwashing, Covid19
- Trial name
- NCT04765540
- Testing
- Low Intensity Nudges, High Intensity Activities, BRAC's business-as-usual
- Where
- 3 sites in Bangladesh
- Volunteers
- 855 people, healthy volunteers welcome
- Sponsor
- The Behavioural Insights Team
SARS (Disease)
Cyclosporine For The Treatment Of COVID-19(+)
Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7 days of an oral formulation of cyclosporine, Neoral (2.5mg/kg PO BID) + standard of care (SOC) or no Neoral + SOC.
- Trial name
- NCT04492891
- Testing
- Cyclosporine, Standard of Care Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bryan Burt, MD
Severe Acute Respiratory Syndrome Coronavirus 2
A Clinical Trial of COVAC-1, a COVID-19 Vaccine, in Generally Healthy Adults
VIDO has developed a vaccine called COVAC-1. The study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike protein is the part of the virus that is responsible for attaching to the surface of host…
- Trial name
- NCT05155982
- Testing
- COVAC-1
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Covid19 Vaccine
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents
The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine compared to placebo in participants aged ≥ 12 to < 18 years.
- Trial name
- NCT04951388
- Testing
- MVC-COV1901(S protein with adjuvant), MVC-COV1901(Saline)
- Where
- 5 sites in Taiwan
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
SARS CoV 2 Infection, Influenza A Virus Infection
Clinical Validation of the NowFuture Digital Flu / COVID Test in Anterior Nasal Samples for Over-the-Counter (OTC) Use in Australia
Prospective clinical study conducted at three sites (with a simulated home environment) in Australia for the clinical validation of the NowFuture Digital Flu / COVID Test.
- Conditions
- SARS CoV 2 Infection, Influenza A Virus Infection, Influenza B Virus Infection
- Trial name
- NCT07743970
- Testing
- Diagnostic test for SARS-CoV-2, influenza A and influenza B
- Where
- 3 sites in Australia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Biocrucible Ltd
COVID
Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE)
The COVID-19 pandemic health crisis forces health institutions to lower their standards of protection as supplies of personal protective equipment decrease despite the safety of front-line workers worldwide .
- Trial name
- VADER (NCT04375774)
- Testing
- FFP2, Facial mask, MFS
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
SARS-CoV-2 Rapid Antigen Test
Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19
Physicians, nurses and hospital attendants currently working at the University Clinic of Respiratory and Allergic Diseases Golnik were invited to participate in the pilot study.
- Trial name
- NCT04716088
- Testing
- Rapid antigen test for SARS CoV2
- Where
- Slovenia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- The University Clinic of Pulmonary and Allergic Diseases Golnik
SARS-CoV-2 Infection Covid19
Differential Leucocyte Count and Covid-19 Diagnosis
To date, the diagnosis of SARS-CoV-2 infection is made by identifying the viral RNA in samples collected through a nasopharyngeal swab or other respiratory samples but this technique, has several limitations for its application…
- Trial name
- NCT04643860
- Testing
- Differential Leucocyte Count (CLDC) device and algorithm
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
SARS-CoV-2 Positive Patients
Follow-up Study of COVID-19 Patients in the District Konstanz
This is a prospective single-center study for the follow-up of SARS-CoV-2 positive patients in the district of Konstanz (LKN). As part of the coronavirus pandemic, patients with SARS-CoV-2 infection are currently being treated in…
- Trial name
- FSC19-KN (NCT04724434)
- Where
- Germany
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Hegau-Bodensee-Klinikum Singen
SARS-CoV-2 (COVID-19) Infection
Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers
The goal of this First in Human Phase 1 clinical trial is to to assess the safety, tolerability, and systemic exposure of single, twice daily (BID) doses and repeated BID doses of ascending dosing by intranasal administration of…
- Trial name
- BID (NCT07095049)
- Testing
- Apo-Si-K170A-C76
- Where
- Israel
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Interna Therapeutics Ltd.
COVID-19
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants…
- Trial name
- NCT04904471
- Testing
- Recombinant COVID-19 vaccine (Sf9 cells)
- Where
- 24 sites in Indonesia, Kenya and 3 more
- Volunteers
- 39,663 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Healthy, Immunization; Infection
BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers
As previously shown, individuals who experienced COVID-19 have developed some protective immunity to reinfection. The magnitude and duration of protection from reinfection conferred by the infection may be weaker after an…
- Trial name
- CoviCompareP (NCT04824638)
- Testing
- 3 doses of BNT162b2 vaccine, 2 dose of BNT162b2 vaccine
- Where
- 11 sites in France
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19, COVID-19 Immunisation
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
This is a phase 1, open-label, randomized clinical trial in males and non-pregnant females, 18 years of age and older, who are in good health, have no known history of COVID-19 or SARS-CoV-2 infection, and meet all other…
- Trial name
- NCT04785144
- Testing
- mRNA-1273, mRNA-1273.351
- Where
- 4 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.